Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2017 | What makes the British Society for Haematology (BSH) Annual Scientific Meeting unique?

Anas Younes • 29 Mar 2017
BSH 2017
Hodgkin Lymphoma

Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains why the British Society for Haematology (BSH) Annual Scientific Meeting is unique at BSH 2017 in Brighton, UK. He focuses on the attendance of global thought leaders, whose meeting results in interesting discussion and actionable items. Prof. Younes also highlights how the BSH meeting agenda is dynamic and responsive to “hot topics”, and that many discussions take place outside of the scheduled program.

More from Anas Younes

1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals